Posts Tagged ‘innovation’

Looking for Real Plants in a Plant-Based Diet

September 18, 2022 — One of the hottest concepts right now in dietary fashion is plant-based diets. It’s on the way to surpassing the dominant theme of the last two decades – low-carb diets. Thus, some really exceptional claims for the benefits of plant-based diets are popping up in scientific literature. Apart from the fanciful nature of some of […]

Locked into the Wrong Debate About Obesity

September 15, 2022 — Public discourse about obesity is often locked into the wrong debate. On one hand, a common view holds that this is a problem for which prevention is the only real answer. People must have good nutrition and active lives by default so that children will not grow into adulthood with obesity. On the other hand, […]

Putting the Best Meds Within Reach for Everyone

September 9, 2022 — Be careful what you wish for, says the wisdom of the ages. It’s all about unintended consequences. Right now, policymakers all over the political spectrum are wishing to solve the problem of drug pricing in the U.S. The simple fact is that drug pricing in the U.S. puts the best, most innovative drugs out of […]

A New Combination Therapy Hits the Mark

August 26, 2022 — Progress keeps coming in the pharmacotherapy for obesity. This week, Novo Nordisk announced that its new combination therapy of semaglutide and cagrilintide hit all its marks in a 32-week phase 2 study of patients with diabetes and excess weight. The combination – Novo is calling it CagriSema – worked better than either semaglutide or cagrilintide […]

Telemedicine or Telehealth for Obesity?

August 10, 2022 — Before the COVID-19 pandemic, we could find lots of talk about the potential of telehealth – and see its potential for extending the reach of obesity care. Translation into action and care delivery, though, was very slow. When the pandemic became a constraint for face to face care delivery, that changed overnight. Telehealth care for […]

Semaglutide SELECT Study: No News Is News

August 4, 2022 — Sometimes the hardest news to digest is no news. This was certainly the case yesterday for Novo Nordisk, the market leader in anti-obesity medicines. Their stock dropped by nearly 13 percent when the company told investors that there would be no news on the semaglutide SELECT study. So why was no news seemingly such big […]

YWM Engage: Bias Meets the Future in Obesity

July 16, 2022 — On the first full day of YWM Engage, it was plain that this was a different sort of convention for OAC. It was smaller. The group was being very cautious because this rotten pandemic, though it’s less of a threat, isn’t over. So the agenda got right down to the business of bringing everyone up […]

Semaglutide for NASH: Disappointing Results

July 2, 2022 — Nonalcoholic steatohepatitis – NASH – has yet again handed drug researchers disappointing results, this time in a study of semaglutide. Researchers presented this phase 2 study at the International Liver Congress in London last weekend. The whole point of a phase 2 study is to see if a drug works for a specific purpose. On […]

What Does a New Era of Obesity Care Look Like?

June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]

The Imperative for Progress in Pediatric Obesity Care

June 23, 2022 — It is, quite simply, inspiring to spend an entire day with with a team of people dedicated to doing nothing but advancing the care of young persons living with obesity. We had this privilege yesterday at the University of Minnesota Center for Pediatric Obesity Medicine (CPOM). These are people dedicating themselves to bringing progress to […]